BridgeMD
Tests treatment safety and results for Longevity
Official title Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
ClinicalTrials.gov ID: NCT07092618
What this study is testing
What is Metformin?
Metformin is an investigational medicine, being studied as a potential treatment for longevity.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this randomized, controlled trial is to evaluate the effectiveness of alternative therapies (metformin alone, with rapamycin, and with low-dose naltrexone) in maintaining weight loss in patients weaning off GLP-1 medications. The main questions it aims to answer are: Whether the combination of metformin, with or without rapamycin or low-dose naltrexone, will be adequate to maintain the relative weight of individuals gradually discontinuing GLP-1 receptor agonist use.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 to 85
You may be able to join if
- Existing AgelessRx patient
- Adults (40 - 85 years of age)
- Any sex
- Any ethnicity
- BMI ≥ 22 kg/m\^2
You likely can't join if
- Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or...
- History of bariatric surgery
- Use of weight-loss medications other than GLP-1s within the past 6 months
- Age \<40 years
- Contraindications to naltrexone, metformin, or rapamycin
- Significant psychiatric illness that may affect participation
See the full eligibility criteria
- Existing AgelessRx patient
- Adults (40 - 85 years of age)
- Any sex
- Any ethnicity
- BMI ≥ 22 kg/m\^2
- Have been on GLP-1s (Wegovy, Ozempic, or a compounded form of GLP-1s) for at least three months before study initiation
- Have lost at least 15 lbs during their GLP-1 use
- Individuals who are denied a longevity product by the AgelessRx medical team will not be asked to participate in any product specific test(s) or questionnaire(s)
- History of bariatric surgery
- Use of weight-loss medications other than GLP-1s within the past 6 months
- Age \<40 years
- Contraindications to naltrexone, metformin, or rapamycin
- Significant psychiatric illness that may affect participation
- Pregnant or breastfeeding individuals
The study team makes the final eligibility decision.
Where it's taking place
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years to 85 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Chicago, Illinois, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.